Eledon Pharmaceuticals (ELDN) Stock Forecast & Price Target

Eledon Pharmaceuticals Inc. has shown promising results with its clinical-stage compound, tegoprubart, particularly in enhancing graft survival and kidney function in transplant patients. The company emphasizes that the safety and tolerability profile of tegoprubart is notably superior to that of tacrolimus, which is widely used in standard care, and this could offer a significant advantage in the treatment landscape. Additionally, the stable estimated glomerular filtration rates (eGFRs) achieved by patients on tegoprubart indicate a potential for improved long-term outcomes in kidney transplantation compared to historical benchmarks.

Eledon Pharmaceuticals Inc. reported a significant net loss of $17.5 million in the third quarter of 2025, a stark contrast to the net income of $77 million reported in the same quarter of 2024, primarily due to the previous year’s non-cash gain from warrant liability changes. Operating expenses decreased slightly year-over-year but remain high relative to the company’s current financial state, highlighting concerns regarding sustainability. Key risks related to the development and commercialization of the company’s lead compound, tegoprubart, include potential clinical trial failures, difficulties in obtaining regulatory approval, and challenges in achieving commercial success due to reimbursement issues and increased competition.